ArticleACS measurement science au2026
High-Sensitivity Magnetic Particle Spectroscopy Platform for Precise, Specific, and Rapid Detection of Infectious Disease and Cancer-Related Biomarkers.
Article in ACS measurement science au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate biosensing using magnetic particle spectroscopy (MPS) depends on the interplay between biomolecular binding and the fidelity of the measurement system. MPS enables wash-free, label-free biosensing by monitoring Brownian relaxation-induced changes in magnetic nanoparticle (MNP) dynamics. However, its practical performance is often limited by a weak signal-to-noise ratio, excitation feedthrough, environmental noise, slow acquisition, and insufficient mass sensitivity. Here, a gradiometer-based MPS system incorporating noise suppression, signal integration, and harmonic detection was developed to monitor relaxation changes upon biomolecular binding. Single-core SHP-25 MNPs were conjugated with recombinant human angiotensin-converting enzyme 2 (ACE2) protein, antinucleoprotein (anti_NP) antibodies, and AS1411 aptamer to target the SARS-CoV-2 receptor-binding domain (RBD), influenza A hemagglutinin type-1, neuraminidase type-1 (H1N1) nucleoprotein, and breast cancer biomarker nucleolin, respectively. Conjugation was validated by FT-IR spectroscopy and DLS to confirm chemical attachment and hydrodynamic size modulation, while ICP-MS was used for iron-mass normalization. Relaxation changes from conjugation and target binding were recorded by MPS. The third-harmonic showed the highest sensitivity to binding-induced relaxation delays, with detection limits of 1 nM (100 fmol) for ACE2 and anti_NP and 12 nM for AS1411. Target-binding yielded statistically significant responses at concentrations as low as 5 nM for RBD, H1N1, and nucleolin. The harmonic ratio R
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.